

# Christopher P Denton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9084581/publications.pdf>

Version: 2024-02-01

312  
papers

30,159  
citations

9784

73  
h-index

5255

165  
g-index

317  
all docs

317  
docs citations

317  
times ranked

18007  
citing authors

#	ARTICLE	IF	CITATIONS
1	Haemodynamic definitions and updated clinical classification of pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801-1913.	6.7	2,583
2	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
3	Updated Clinical Classification of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S43-S54.	2.8	1,919
4	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.9	1,705
5	Systemic sclerosis. <i>Lancet, The</i> , 2017, 390, 1685-1699.	13.7	1,423
6	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1809-1815.	0.9	1,017
7	Interstitial Lung Disease in Systemic Sclerosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1248-1254.	5.6	930
8	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.9	794
9	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1340-1349.	0.9	633
10	A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. <i>Arthritis and Rheumatism</i> , 2006, 54, 3962-3970.	6.7	632
11	Systemic sclerosis. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15002.	30.5	587
12	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. <i>Lancet, The</i> , 2016, 387, 2630-2640.	13.7	505
13	Recombinant human anti- $\alpha$ transforming growth factor $\beta$ 1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. <i>Arthritis and Rheumatism</i> , 2007, 56, 323-333.	6.7	415
14	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 32-38.	0.9	394
15	Prediction of Pulmonary Complications and Long-Term Survival in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2014, 66, 1625-1635.	5.6	354
16	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 963-974.	10.7	348
17	CT Features of Lung Disease in Patients with Systemic Sclerosis: Comparison with Idiopathic Pulmonary Fibrosis and Nonspecific Interstitial Pneumonia. <i>Radiology</i> , 2004, 232, 560-567.	7.3	338
18	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 11-18.	1.7	321

#	ARTICLE	IF	CITATIONS
19	Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1355-1360.	0.9	275
20	Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. <i>Arthritis and Rheumatism</i> , 1999, 42, 2646-2655.	6.7	274
21	Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension. <i>American Journal of Pathology</i> , 2015, 185, 1850-1858.	3.8	267
22	Short-term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1670-1678.	5.6	247
23	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 212-220.	0.9	236
24	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020, 19, 102458.	5.8	231
25	Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2013, 40, 435-446.	2.0	226
26	Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. <i>Arthritis and Rheumatism</i> , 2009, 60, 2142-2155.	6.7	206
27	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. <i>PLoS Genetics</i> , 2011, 7, e1002178.	3.5	201
28	Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1235-1242.	0.9	199
29	Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. <i>Arthritis Research and Therapy</i> , 2005, 7, R1113.	3.5	198
30	Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. <i>Thorax</i> , 2013, 68, 436-441.	5.6	193
31	A Polymorphism in the <i>CTGF</i> Promoter Region Associated with Systemic Sclerosis. <i>New England Journal of Medicine</i> , 2007, 357, 1210-1220.	27.0	185
32	Ligand-Dependent Genetic Recombination in Fibroblasts. <i>American Journal of Pathology</i> , 2002, 160, 1609-1617.	3.8	183
33	ImmunoChIP Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	6.2	182
34	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2087-2093.	0.9	168
35	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 125-136.	5.6	163
36	Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory model. <i>Arthritis and Rheumatism</i> , 2007, 56, 2422-2431.	6.7	160

#	ARTICLE	IF	CITATIONS
37	Interstitial lung disease in connective tissue disease—mechanisms and management. <i>Nature Reviews Rheumatology</i> , 2014, 10, 728-739.	8.0	160
38	Mechanisms and consequences of fibrosis in systemic sclerosis. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 134-144.	3.2	158
39	Autoantibodies as predictive tools in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2010, 6, 112-116.	8.0	156
40	Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis—associated interstitial lung disease are not predictive of disease progression. <i>Arthritis and Rheumatism</i> , 2007, 56, 2005-2012.	6.7	155
41	Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. <i>Arthritis Research and Therapy</i> , 2013, 15, 215.	3.5	149
42	BSR and BHPR guideline for the treatment of systemic sclerosis. <i>Rheumatology</i> , 2016, 55, 1906-1910.	1.9	147
43	Predictors of progression in systemic sclerosis patients with interstitial lung disease. <i>European Respiratory Journal</i> , 2020, 55, 1902026.	6.7	134
44	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.9	132
45	Fibroblast-specific Expression of a Kinase-deficient Type II Transforming Growth Factor $\beta$ (TGF $\beta$ 2) Receptor Leads to Paradoxical Activation of TGF $\beta$ 2 Signaling Pathways with Fibrosis in Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2003, 278, 25109-25119.	3.4	126
46	Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 465-476.	5.6	123
47	Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the fasScinate clinical trial in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1362-1371.	0.9	122
48	Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 275.	1.6	121
49	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENCIS trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 96-106.	10.7	118
50	Raynaud phenomenon and digital ulcers in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 208-221.	8.0	115
51	Clinical and Serological Hallmarks of Systemic Sclerosis Overlap Syndromes. <i>Journal of Rheumatology</i> , 2011, 38, 2406-2409.	2.0	110
52	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 299-311.	5.6	110
53	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. <i>Arthritis and Rheumatism</i> , 2008, 59, 699-705.	6.7	109
54	Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 2015-2024.	1.9	108

#	ARTICLE	IF	CITATIONS
55	Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 422-426.	0.9	108
56	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.9	107
57	Gastrointestinal manifestations of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 247-256.	1.7	106
58	Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 650-660.	5.6	105
59	Tocilizumab Prevents Progression of Early Systemic Sclerosisâ€Associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1301-1310.	5.6	104
60	An Essential Role for Resident Fibroblasts in Experimental Lung Fibrosis Is Defined by Lineage-Specific Deletion of High-Affinity Type II Transforming Growth Factor Î² Receptor. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 249-261.	5.6	103
61	Sclerodermaâ€clinical and pathological advances. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 271-290.	3.3	102
62	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019, 10, 4955.	12.8	100
63	Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. <i>Rheumatology</i> , 2010, 49, 1770-1775.	1.9	96
64	Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 718-721.	0.9	96
65	The Pathogenesis of Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 367-382.	1.9	96
66	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1124-1131.	0.9	96
67	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1975.	7.4	95
68	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 103-109.	0.9	93
69	A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. <i>Genome Medicine</i> , 2017, 9, 27.	8.2	92
70	Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tightâ€skin mouse. <i>Arthritis and Rheumatism</i> , 2003, 48, 1979-1991.	6.7	84
71	Fast track algorithm: How to differentiate a â€scleroderma patternâ€from a â€non-scleroderma patternâ€. <i>Autoimmunity Reviews</i> , 2019, 18, 102394.	5.8	79
72	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 648-656.	0.9	79

#	ARTICLE	IF	CITATIONS
73	A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis. PLoS ONE, 2015, 10, e0126015.	2.5	77
74	Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. European Respiratory Journal, 2018, 51, 1701197.	6.7	76
75	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Research and Therapy, 2018, 20, 17.	3.5	75
76	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	5.6	75
77	Pulmonary hypertension in systemic sclerosis. Rheumatic Disease Clinics of North America, 2003, 29, 335-349.	1.9	74
78	Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2018, 70, 1634-1643.	5.6	74
79	Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Annals of the Rheumatic Diseases, 2016, 75, 1770-1776.	0.9	72
80	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Annals of the Rheumatic Diseases, 2020, 79, 618-625.	0.9	71
81	Systemic Sclerosis-associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-approved Therapies in Clinical Practice. Arthritis and Rheumatology, 2022, 74, 13-27.	5.6	71
82	A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Annals of the Rheumatic Diseases, 2020, 79, 1600-1607.	0.9	69
83	A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography. Arthritis and Rheumatology, 2018, 70, 903-911.	5.6	65
84	Inducible Lineage-Specific Deletion of $TGF\beta 2$ in Fibroblasts Defines a Pivotal Regulatory Role during Adult Skin Wound Healing. Journal of Investigative Dermatology, 2009, 129, 194-204.	0.7	64
85	Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension. Arthritis and Rheumatology, 2016, 68, 484-493.	5.6	64
86	Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis. Clinical Science, 2016, 130, 575-586.	4.3	64
87	Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology, 2016, 55, 115-119.	1.9	62
88	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. Journal of Scleroderma and Related Disorders, 2017, 2, 115-120.	1.7	62
89	Targeted therapy comes of age in scleroderma. Trends in Immunology, 2005, 26, 596-602.	6.8	61
90	Partially Evoked Epithelial-Mesenchymal Transition (EMT) Is Associated with Increased $TGF\beta 2$ Signaling within Lesional Scleroderma Skin. PLoS ONE, 2015, 10, e0134092.	2.5	61

#	ARTICLE	IF	CITATIONS
91	Changes in macrophage transcriptome associate with systemic sclerosis and mediate <i>c</i> GSDMA contribution to disease risk. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 596-601.	0.9	60
92	Functional disability and its predictors in systemic sclerosis: a study from the DeSSciper project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	1.9	60
93	Major lung complications of systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 511-527.	8.0	60
94	Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors. <i>Rheumatology</i> , 2013, 52, 1824-1831.	1.9	59
95	Activation of Key Profibrotic Mechanisms in Transgenic Fibroblasts Expressing Kinase-deficient Type II Transforming Growth Factor- $\beta$ Receptor (T $\beta$ RIII <sup>YK</sup> ). <i>Journal of Biological Chemistry</i> , 2005, 280, 16053-16065.	3.4	58
96	Cardiac fibroblast-specific p38 $\beta$ MAP kinase promotes cardiac hypertrophy <i>via</i> a putative paracrine interleukin-6 signaling mechanism. <i>FASEB Journal</i> , 2018, 32, 4941-4954.	0.5	57
97	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Associated Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 674-684.	5.6	57
98	Gender-related differences in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020, 19, 102494.	5.8	55
99	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	1.9	53
100	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018, 57, 1623-1631.	1.9	53
101	Pathogenesis of systemic sclerosis associated interstitial lung disease. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 6-16.	1.7	53
102	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. <i>Rheumatology</i> , 2022, 61, 1600-1609.	1.9	53
103	New insight on the Xq28 association with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 2032-2038.	0.9	52
104	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	5.0	52
105	Fibroblast-specific perturbation of transforming growth factor $\beta$ signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: Exaggerated response to alveolar epithelial injury in a novel mouse model. <i>Arthritis and Rheumatism</i> , 2008, 58, 1175-1188.	6.7	51
106	Observational Study of Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2010, 37, 116-124.	2.0	51
107	STAT3 controls COL1A2 enhancer activation cooperatively with JunB, regulates type I collagen synthesis posttranscriptionally, and is essential for lung myofibroblast differentiation. <i>Molecular Biology of the Cell</i> , 2018, 29, 84-95.	2.1	51
108	Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. <i>Rheumatology</i> , 2019, 58, 567-579.	1.9	51



#	ARTICLE	IF	CITATIONS
109	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 724-726.	0.9	51
110	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.9	50
111	Endothelin axis polymorphisms in patients with scleroderma. <i>Arthritis and Rheumatism</i> , 2006, 54, 3034-3042.	6.7	49
112	Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2370-2379.	5.6	49
113	Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018, 70, 162-170.	5.6	48
114	Endothelial Injury in a Transforming Growth Factor $\beta$ -Dependent Mouse Model of Scleroderma Induces Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatism</i> , 2013, 65, 2928-2939.	6.7	47
115	Brief Report: <i>IRF4</i> Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. <i>Arthritis and Rheumatology</i> , 2016, 68, 2338-2344.	5.6	46
116	Old medications and new targeted therapies in systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 1944-1953.	1.9	45
117	Validation of a Novel Radiographic Scoring System for Calcinosis Affecting the Hands of Patients With Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2015, 67, 425-430.	3.4	44
118	Fibroblast-specific deletion of IL-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction. <i>JCI Insight</i> , 2019, 4, .	5.0	44
119	Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 61-71.	1.7	43
120	Thrombospondin 1 is a key mediator of transforming growth factor $\beta$ -mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism. <i>Fibrogenesis and Tissue Repair</i> , 2011, 4, 9.	3.4	42
121	Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine. <i>Stem Cell Research and Therapy</i> , 2017, 8, 23.	5.5	42
122	Influence of <i>TYK2</i> in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1521-1526.	0.9	41
123	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	5.6	41
124	Impaired Bone Morphogenetic Protein Receptor II Signaling in a Transforming Growth Factor $\beta$ -Dependent Mouse Model of Pulmonary Hypertension and in Systemic Sclerosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 665-677.	5.6	39
125	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1242-1248.	0.9	39
126	The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis. <i>PLoS ONE</i> , 2013, 8, e54419.	2.5	38



#	ARTICLE	IF	CITATIONS
127	Gut fibrosis with altered colonic contractility in a mouse model of scleroderma. <i>Rheumatology</i> , 2012, 51, 1989-1998.	1.9	36
128	Targeted therapies for systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2013, 9, 451-464.	8.0	36
129	Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1736-1740.	0.9	34
130	Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). <i>Arthritis Research and Therapy</i> , 2019, 21, 217.	3.5	34
131	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	3.9	34
132	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. <i>Rheumatology</i> , 2021, 60, 5028-5041.	1.9	34
133	Association of Defective Regulation of Autoreactive Interleukin-6-Producing Transitional B Lymphocytes With Disease in Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018, 70, 450-461.	5.6	33
134	Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. <i>Rheumatology</i> , 2020, 59, 2625-2636.	1.9	33
135	A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R85.	3.5	32
136	Towards developing criteria for scleroderma renal crisis: A scoping review. <i>Autoimmunity Reviews</i> , 2017, 16, 407-415.	5.8	32
137	Systemic sclerosis in adults. Part I: Clinical features and pathogenesis. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 937-954.	1.2	32
138	Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. <i>Journal of Rheumatology</i> , 2018, 45, 405-410.	2.0	31
139	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1576-1582.	0.9	31
140	Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 212-218.	1.7	31
141	Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. <i>Rheumatology</i> , 2015, 54, 144-151.	1.9	30
142	Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression. <i>Respirology</i> , 2021, 26, 461-468.	2.3	30
143	Systemic sclerosis: from pathogenesis to targeted therapy. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S3-7.	0.8	30
144	Derivation and External Validation of a Prediction Rule for Five-Year Mortality in Patients With Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 993-1003.	5.6	29

#	ARTICLE	IF	CITATIONS
145	Cognitive dysfunction in autoimmune rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2020, 22, 78.	3.5	28
146	Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 912.	9.1	28
147	Transgenic analysis of scleroderma: understanding key pathogenic events in vivo. <i>Autoimmunity Reviews</i> , 2004, 3, 285-293.	5.8	27
148	Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 170-174.	1.7	27
149	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. <i>Rheumatology</i> , 2020, 59, 1684-1694.	1.9	27
150	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1049-1058.	5.6	27
151	Therapeutic targets in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2007, 9, S6.	3.5	25
152	Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma. <i>Arthritis Research and Therapy</i> , 2010, 12, R69.	3.5	25
153	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 42-49.	1.7	25
154	Transforming Growth Factor $\beta$ 2 Activation Primes Canonical Wnt Signaling Through Downregulation of Axin2. <i>Arthritis and Rheumatology</i> , 2018, 70, 932-942.	5.6	25
155	Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 184-193.	2.1	25
156	Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure. <i>Arthritis and Rheumatology</i> , 2019, 71, 805-816.	5.6	25
157	Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020, 72, 723-733.	3.4	25
158	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 24-32.	1.7	25
159	Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1040-1047.	0.9	24
160	Pathogenic Activation of Mesenchymal Stem Cells Is Induced by the Disease Microenvironment in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1361-1374.	5.6	23
161	Cai et al. reply. <i>Nature</i> , 2009, 458, E9-E10.	27.8	22
162	Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 73.	3.5	21

#	ARTICLE	IF	CITATIONS
163	Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 813-817.	1.9	21
164	Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1584-1593.	0.9	21
165	Nintedanib in Patients With Systemic Sclerosisâ€“Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. <i>Arthritis and Rheumatology</i> , 2022, 74, 518-526.	5.6	21
166	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 128-132.	0.9	20
167	Should all digital ulcers be included in future clinical trials of systemic sclerosis-related digital vasculopathy?. <i>Medical Hypotheses</i> , 2018, 116, 101-104.	1.5	20
168	Genomic Risk Score impact on susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 118-127.	0.9	20
169	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	1.9	20
170	Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 378-391.	6.5	19
171	Animal models of scleroderma: lessons from transgenic and knockout mice. <i>Current Opinion in Rheumatology</i> , 2009, 21, 630-635.	4.3	18
172	Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. <i>Nature Reviews Rheumatology</i> , 2022, 18, 276-285.	8.0	18
173	Resolution of paraneoplastic PM/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour. <i>Rheumatology</i> , 2017, 56, 317-318.	1.9	17
174	COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 58-65.	1.7	17
175	Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2019, 46, 603-608.	2.0	16
176	Analysis of Anti-RNA Polymerase III Antibody-positive Systemic Sclerosis and Altered GPATCH2L and CTNND2 Expression in Scleroderma Renal Crisis. <i>Journal of Rheumatology</i> , 2020, 47, 1668-1677.	2.0	16
177	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018, 70, 1829-1834.	5.6	15
178	Distinctive clinical phenotype of anti-centromere antibody-positive diffuse systemic sclerosis. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky002.	0.7	15
179	Optimisation of botulinum toxin type a treatment for the management of Raynaudâ€™s phenomenon using a dorsal approach: a prospective case series. <i>Clinical Rheumatology</i> , 2019, 38, 3669-3676.	2.2	15
180	Ilprost for COVID-19-related vasculopathy. <i>Lancet Rheumatology</i> , The, 2020, 2, e582-e583.	3.9	15

#	ARTICLE	IF	CITATIONS
181	Scleroderma Lung Involvement, Autoantibodies, and Outcome Prediction: The Confounding Effect of Time. <i>Journal of Rheumatology</i> , 2017, 44, 404-406.	2.0	14
182	Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature. <i>Arthritis Research and Therapy</i> , 2017, 19, 156.	3.5	14
183	Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 61-71.	1.7	14
184	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016, 68, 167-178.	3.4	13
185	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 152-157.	1.9	13
186	An interim report of the Scleroderma Clinical Trials Consortium working groups. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 17-27.	1.7	13
187	Challenges in systemic sclerosis trial design. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, S3-S7.	3.4	13
188	Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. <i>Rheumatology</i> , 2022, 62, 234-242.	1.9	13
189	Molecular Basis for Dysregulated Activation of $\alpha 5$ in the Vascular Remodeling of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018, 70, 920-931.	5.6	12
190	Defining genetic risk factors for scleroderma-associated interstitial lung disease. <i>Clinical Rheumatology</i> , 2020, 39, 1173-1179.	2.2	12
191	STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2021, 48, 1295-1298.	2.0	12
192	Scleroderma mimics – Clinical features and management. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101489.	3.3	12
193	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 66-76.	1.7	12
194	A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis. <i>JAMA Dermatology</i> , 2021, 157, 851-858.	4.1	12
195	Clinical features and management of erythromelalgia: long term follow-up of 46 cases. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 80-84.	0.8	12
196	Diffuse cutaneous systemic sclerosis following SARS-Co V-2 vaccination. <i>Journal of Autoimmunity</i> , 2022, 128, 102812.	6.5	12
197	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2018, 58, 254-259.	1.9	11
198	Patient experiences of digital ulcer development and evolution in systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 2156-2158.	1.9	11

#	ARTICLE	IF	CITATIONS
199	Rituximab for the treatment of systemic sclerosis-interstitial lung disease. <i>Rheumatology</i> , 2021, 60, 489-491.	1.9	11
200	Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENCIS trial. <i>Rheumatology</i> , 2022, 61, 4397-4408.	1.9	11
201	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 124-133.	0.8	11
202	Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	11
203	High proton pump inhibitor exposure increases risk of calcinosis in systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 849-854.	1.9	10
204	ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies. <i>Rheumatology</i> , 2021, 60, 5509-5516.	1.9	10
205	Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (SclerID) questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 507-515.	0.9	10
206	Intravenous immunoglobulin therapy for severe gastrointestinal involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S168-70.	0.8	10
207	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. <i>Rheumatology</i> , 2022, 61, 4384-4396.	1.9	10
208	Management of Renal Involvement in Scleroderma. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 106-118.	1.4	9
209	Analysis of <i>ATP8B4</i> F436L Missense Variant in a Large Systemic Sclerosis Cohort. <i>Arthritis and Rheumatology</i> , 2017, 69, 1337-1338.	5.6	9
210	Deep phenotyping detects a pathological CD4+ T-cell complosome signature in systemic sclerosis. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1010-1013.	10.5	9
211	Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients. <i>Rheumatology</i> , 2021, 60, 3945-3946.	1.9	9
212	Selective deletion of connective tissue growth factor attenuates experimentally-induced pulmonary fibrosis and pulmonary arterial hypertension. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 134, 105961.	2.8	9
213	The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 234.	3.5	9
214	Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study. <i>Lancet Rheumatology</i> , The, 2022, 4, e243-e246.	3.9	9
215	Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. <i>Arthritis Research and Therapy</i> , 2011, 13, 114.	3.5	8
216	Reduced levels of S-nitrosothiols in plasma of patients with systemic sclerosis and Raynaud's phenomenon. <i>Vascular Pharmacology</i> , 2014, 63, 178-181.	2.1	8

#	ARTICLE	IF	CITATIONS
217	Elevated kynurenine levels in diffuse cutaneous and anti-RNA polymerase III positive systemic sclerosis. <i>Clinical Immunology</i> , 2019, 199, 18-24.	3.2	8
218	Interaction between the promoter MUC5B polymorphism and mucin expression: is there a difference according to ILD subtype?. <i>Thorax</i> , 2020, 75, 901-903.	5.6	8
219	Novel therapeutic strategies in scleroderma. <i>Current Rheumatology Reports</i> , 1999, 1, 22-27.	4.7	7
220	Therapy of pulmonary arterial hypertension in systemic sclerosis: An update. <i>Current Rheumatology Reports</i> , 2007, 9, 158-164.	4.7	7
221	Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2019, 21, 81.	3.5	7
222	Autoimmunity and immunodeficiency at the crossroad: autoimmune disorders as the presenting feature of selective IgM deficiency. <i>BMJ Case Reports</i> , 2019, 12, e223180.	0.5	7
223	Patient perception of disease burden in diffuse cutaneous systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 66-76.	1.7	7
224	Exploring molecular pathology of chronic kidney disease in systemic sclerosis by analysis of urinary and serum proteins. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa083.	0.7	7
225	Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis. <i>Rheumatology</i> , 2022, 61, 781-786.	1.9	7
226	News and failures from recent treatment trials in systemic sclerosis. <i>European Journal of Rheumatology</i> , 2020, 7, 242.	0.6	7
227	Systemic sclerosis in adults. Part II: management and therapeutics. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 957-978.	1.2	7
228	Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study. <i>Lancet Rheumatology</i> , The, 2022, 4, e507-e516.	3.9	7
229	Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes. <i>Scientific Reports</i> , 2022, 12, .	3.3	7
230	Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study. <i>European Heart Journal Cardiovascular Imaging</i> , 2023, 24, 463-471.	1.2	7
231	Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2017, 19, 45.	3.5	6
232	The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-219348.	0.5	6
233	Comparing paediatric- and adult-onset linear morphea in a large tertiary-referral scleroderma centre. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 102-108.	1.7	6
234	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.201594.	2.0	6

#	ARTICLE	IF	CITATIONS
235	Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practice. <i>Lancet Respiratory Medicine</i> , 2021, 9, 560-562.	10.7	6
236	Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2022, 61, 1948-1956.	1.9	6
237	Systemic sclerosis phase III clinical trials: Hope on the horizon?. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 193-200.	1.7	5
238	Proteomic Analysis of Human Scleroderma Fibroblasts Response to Transforming Growth Factor- $\beta$ . <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800069.	1.6	5
239	Induction of Pro-Fibrotic CLIC4 in Dermal Fibroblasts by TGF- $\beta$ 2/Wnt3a Is Mediated by GLI2 Upregulation. <i>Cells</i> , 2022, 11, 530.	4.1	5
240	Development of systemic sclerosis in transgender females: a case series and review of the literature. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 50-52.	0.8	5
241	A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis. <i>Rheumatology</i> , 0, , .	1.9	5
242	Scleroderma Lung Study II "clarity or obfuscation?". <i>Lancet Respiratory Medicine</i> , 2016, 4, 678-679.	10.7	4
243	Use of Patterned Collagen Coated Slides to Study Normal and Scleroderma Lung Fibroblast Migration. <i>Scientific Reports</i> , 2017, 7, 2628.	3.3	4
244	Challenges in physician-patient communication for optimal management of systemic sclerosis-associated interstitial lung disease: a discourse analysis. <i>Clinical Rheumatology</i> , 2020, 39, 2989-2998.	2.2	4
245	Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS). <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 146-153.	1.7	4
246	PASTUL questionnaire: a tool for self-assessment of scleroderma skin during the COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 819-820.	0.9	4
247	Reduced exercise capacity in patients with systemic sclerosis is associated with lower peak tissue oxygen extraction: a cardiovascular magnetic resonance-augmented cardiopulmonary exercise study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 118.	3.3	4
248	Systemic Sclerosis. <i>European Medical Journal Rheumatology</i> , 0, , 100-109.	0.0	4
249	312. "Perturbed Response to Experimental Renal Injury in a Mouse Model of Systemic Sclerosis. <i>Rheumatology</i> , 2014, 53, i176-i176.	1.9	3
250	320. "The Prognosis of Scleroderma Renal Crisis in RNA-Polymerase III Antibody-Positive Compared to Rna-Polymerase III Antibody-Negative Patients. <i>Rheumatology</i> , 2014, 53, i179-i179.	1.9	3
251	Reply. <i>Arthritis and Rheumatology</i> , 2016, 68, 1789-1790.	5.6	3
252	Transforming growth factor- $\beta$ 2-induced CUX1 isoforms are associated with fibrosis in systemic sclerosis lung fibroblasts. <i>Biochemistry and Biophysics Reports</i> , 2016, 7, 246-252.	1.3	3



#	ARTICLE	IF	CITATIONS
253	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. <i>PLoS ONE</i> , 2018, 13, e0209343.	2.5	3
254	SAT0296â€¦FAST TRACK ALGORITHM: HOW TO DIFFERENTIATE A SCLERODERMA PATTERN FROM A NON-SCLERODERMA PATTERN. , 2019, , .		3
255	Improving access to digital ulcer care through nurseâ€œled clinic: a service evaluation. <i>Musculoskeletal Care</i> , 2020, 18, 92-97.	1.4	3
256	Things left unsaid: important topics that are not discussed between patients with systemic sclerosis, their carers and their healthcare professionalsâ€œa discourse analysis. <i>Clinical Rheumatology</i> , 2021, 40, 1399-1407.	2.2	3
257	Hand disease in scleroderma: a clinical correlate for chronic hand transplant rejection. <i>SpringerPlus</i> , 2013, 2, 577.	1.2	2
258	Pulmonary Complications of Connective Tissue Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 145-146.	2.1	2
259	THU0354â€¦MACHINE LEARNING CLASSIFICATION OF SKIN GENE EXPRESSION IDENTIFIES A SUBSET OF SYSTEMIC SCLEROSIS PATIENTS MOST LIKELY TO SHOW CLINICAL IMPROVEMENT IN RESPONSE TO ABATACEPT. , 2019, , .		2
260	Challenges in evidence-based therapy for systemic sclerosis associated interstitial lung disease. <i>Lancet Respiratory Medicine</i> , 2020, 8, 226-227.	10.7	2
261	Autologous fat transfer in the successful treatment of upper limb linear morphoea. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 183.	0.8	2
262	Data on CUX1 isoforms in idiopathic pulmonary fibrosis lung and systemic sclerosis skin tissue sections. <i>Data in Brief</i> , 2016, 8, 1377-1380.	1.0	1
263	Combining Unsupervised and Supervised Learning for Discovering Disease Subclasses. , 2016, , .		1
264	O16â€œA study examining the reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: challenges and insights for future clinical trial design. <i>Rheumatology</i> , 2018, 57, .	1.9	1
265	E074â€œDeveloping a molecular classifier for scleroderma spectrum disorders to augment clinical categorisation. <i>Rheumatology</i> , 2019, 58, .	1.9	1
266	Combining Data Sets as Well as Therapies Shows Improved Outcome in Connective Tissue Diseaseâ€œAssociated Pulmonary Hypertension. <i>Arthritis and Rheumatology</i> , 2021, 73, 725-727.	5.6	1
267	P154â€œHigh-density proteomic analysis of skin blister fluid and plasma in systemic sclerosis identifies local and systemic differences for key proteins. <i>Rheumatology</i> , 2021, 60, .	1.9	1
268	Systemic Sclerosis, Scleroderma. , 2006, , 369-379.		1
269	Rheumatologists have an important role in the management of interstitial lung disease (ILD): a cross-speciality, multi-centre, U.K. perspective. <i>Rheumatology</i> , 2022, , .	1.9	1
270	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 124-133.	0.8	1

#	ARTICLE	IF	CITATIONS
271	Three Cases of Systemic Sclerosis Within One Family With Different Antibodies and Clinical Features. <i>Journal of Rheumatology</i> , 2022, 49, 544-546.	2.0	1
272	P227â€fMolecular and functional characterisation of distinct resident and migratory skin fibroblast populations in systemic sclerosis. <i>Rheumatology</i> , 2022, 61, .	1.9	1
273	A Novel Transgenic Mouse Model for Systemic Sclerosis with Balanced Upregulation of Tgff <sup>2</sup> Signalling Pathways. <i>Clinical Science</i> , 2003, 104, 1P-1P.	0.0	0
274	Monocyte Chemoattractant Protein-3 (Mcp-3) as a Mediator of Fibrosis in Scleroderma. <i>Clinical Science</i> , 2003, 104, 13P-13P.	0.0	0
275	Expression and Function of Monocyte Chemoattractant Protein-3 (MCP-3) in Scleroderma. <i>Clinical Science</i> , 2003, 104, 47P-47P.	0.0	0
276	029.â€fAssociation of Anti-PM/SCL Antibody with Risk of Malignancy in Scleroderma. <i>Rheumatology</i> , 0, , .	1.9	0
277	283.â€fEndothelin Receptor Blockade Prevents Development of Pulmonary Hypertension in a Mouse Model of Scleroderma. <i>Rheumatology</i> , 0, , .	1.9	0
278	Twoâ€dimensional knowledgeâ€based volumetric reconstruction of the right ventricle documents shortâ€term improvement in pulmonary hypertension. <i>Echocardiography</i> , 2017, 34, 817-824.	0.9	0
279	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 242-242.	5.6	0
280	059.â€fTHE DISTINCTIVE CLINICAL PHENOTYPE OF ANTI-CENTROMERE ANTIBODYâ€POSITIVE DIFFUSE SYSTEMIC SCLEROSIS. <i>Rheumatology</i> , 2017, 56, .	1.9	0
281	Reply. <i>Arthritis and Rheumatology</i> , 2018, 70, 974-974.	5.6	0
282	O17â€fInterleukin 31 promotes pathogenic mechanisms in scleroderma and induces skin fibrosis in mice. <i>Rheumatology</i> , 2018, 57, .	1.9	0
283	199â€fFrequency and clinical association of rare antibodies in a large connective tissue disease cohort. <i>Rheumatology</i> , 2018, 57, .	1.9	0
284	206â€fProton pump inhibitor use is associated with calcinosis in systemic sclerosis. <i>Rheumatology</i> , 2018, 57, .	1.9	0
285	O13â€fA simple classification of systemic sclerosis using subset and autoantibodies can discriminate well between distinct outcome groups. <i>Rheumatology</i> , 2018, 57, .	1.9	0
286	205â€fSerum tryptophan and kynurenine levels are altered in systemic sclerosis patients and show distinct clinical and autoantibody associations suggesting potential role in pathogenesis. <i>Rheumatology</i> , 2018, 57, .	1.9	0
287	198â€fCritical role of the prolyl 3-hydroxylase LEPREL1 in scleroderma-related fibrosis. <i>Rheumatology</i> , 2018, 57, .	1.9	0
288	i067â€fEvaluation and management of skin fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2018, 57, .	1.9	0

#	ARTICLE	IF	CITATIONS
289	O06â€fProlyl 3-hydroxylase 2 is a candidate gene in scleroderma involved in collagen synthesis and fibrosis. Rheumatology, 2019, 58, .	1.9	0
290	226â€fDisease-specific autoantibodies associate with remarkably different risk of development of significant lung fibrosis in systemic sclerosis. Rheumatology, 2019, 58, .	1.9	0
291	I163â€fAnalysis of the DUO Registry UK data: the effect of NHS Englandâ€™s sildenafil and bosentan clinical commissioning policy. Rheumatology, 2019, 58, .	1.9	0
292	E080â€fTwo cases of rapidly progressive diffuse cutaneous systemic sclerosis treated with autologous haematopoietic stem cell transplant. Rheumatology, 2019, 58, .	1.9	0
293	Latent Class Multi-Label Classification to Identify Subclasses of Disease for Improved Prediction. , 2019, , .		0
294	O17â€fSystemic sclerosis fibroblasts show defective activation by coagulation factor XIII in vitro: implications for impaired wound healing in SSc. Rheumatology, 2019, 58, .	1.9	0
295	I114â€fFibrosis: status of phase II and III clinical trials for skin and lung in systemic sclerosis. Rheumatology, 2019, 58, .	1.9	0
296	225â€fDisease duration and autoantibodies determine distinct skin score trajectories in diffuse cutaneous systemic sclerosis. Rheumatology, 2019, 58, .	1.9	0
297	SAT0254â€f...VASODILATOR THERAPY IN THE LONG TERM PREVENTION OF MYOCARDIAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM DESSCIPHER INCEPTION COHORT STUDY. , 2019, , .		0
298	P151â€fForced vital capacity in patients with systemic sclerosis associated pulmonary fibrosis: predictors of meaningful decline. Rheumatology, 2020, 59, .	1.9	0
299	P152â€fSkin score trajectory associates with survival and pulmonary outcome in diffuse cutaneous systemic sclerosis. Rheumatology, 2020, 59, .	1.9	0
300	P154â€fStage and subset specific profiles of fibrogenesis highlighted through analysis of serum markers across the scleroderma spectrum. Rheumatology, 2020, 59, .	1.9	0
301	P156â€fUnderstanding the associations and impact of severe gastrointestinal involvement in systemic sclerosis: a structured approach. Rheumatology, 2020, 59, .	1.9	0
302	P155â€fCo-existence of scleroderma hallmark autoantibodies associates with distinct clinical phenotype. Rheumatology, 2020, 59, .	1.9	0
303	Unravelling extracellular matrix biomarkers in systemic sclerosis. Lancet Rheumatology, The, 2021, 3, e162-e163.	3.9	0
304	P151â€fSelf-assessment of scleroderma skin thickness: development and evaluation of the PASTUL questionnaire. Rheumatology, 2021, 60, .	1.9	0
305	P155â€fModelling calcinosis in systemic sclerosis through disease microenvironment-stem cell interactions: effect of novel therapeutic peptide RP832c. Rheumatology, 2021, 60, .	1.9	0
306	P157â€fPotential benefit of intravenous immunoglobulin in connective tissue disease associated interstitial lung diseases. Rheumatology, 2021, 60, .	1.9	0

#	ARTICLE	IF	CITATIONS
307	O18â€fIntegrated molecular analysis of systemic sclerosis skin and blood shows significant differences between major autoantibody subgroups. <i>Rheumatology</i> , 2021, 60, .	1.9	0
308	Connective Tissue Disease-Associated Pulmonary Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2008, 7, bmi-bmi.	0.1	0
309	Systemic Sclerosis and Other Connective Tissue Diseases. <i>Advances in Pulmonary Hypertension</i> , 2017, 16, 55-60.	0.1	0
310	Developing a quantitative tool to evaluate dermal fibrosis in systemic sclerosis patients: a case-control study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 172-173.	0.8	0
311	P229â€fIntegrated analysis of dermal blister fluid proteomics and skin biopsy transcriptomics gives new insight into pathogenesis of systemic sclerosis. <i>Rheumatology</i> , 2022, 61, .	1.9	0
312	P231â€fTargeting the Rho/MRTF-A pathway inhibits growth factor and cytokine release but enhances efferocytosis in scleroderma macrophages. <i>Rheumatology</i> , 2022, 61, .	1.9	0